STOCK TITAN

Schrodinger, Inc. - SDGR STOCK NEWS

Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.

Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.

Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.

Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.

Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.

Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.

Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $25.54 per share and vest over four years, while the RSUs also vest over four years. These grants were made as a material inducement to the employees' acceptance of employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
Rhea-AI Summary
Schrödinger (SDGR) will report its first quarter 2024 financial results on May 1, 2024, after the markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed on Schrödinger's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
-
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) presented the discovery of SGR-1505, its MALT1 inhibitor, at the ACS Spring 2024 Meeting. SGR-1505 is being evaluated in a Phase 1 study for B-cell malignancies. Schrödinger's computational platform expedited the discovery process, leading to the selection of SGR-1505 as the development candidate in just 10 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted stock options and RSUs to newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The stock options have an exercise price of $26.04 per share and a ten-year term, while the RSUs vest over four years. These grants were made to attract talent and align employee interests with company growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary
Schrödinger, Inc. (SDGR) achieved a 44% increase in fourth-quarter software revenue, totaling $68.7 million, and reported 20% annual total revenue growth, reaching $216.7 million. The company expects 6% to 13% software revenue growth in 2024. Schrödinger's CEO, Ramy Farid, highlighted the progress made in 2023, focusing on platform advancements and pipeline expansion, including two clinical-stage programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.84%
Tags
-
Rhea-AI Summary
Schrödinger (SDGR) to participate in key healthcare and biopharma conferences in March 2024, offering investors insights into the company's innovative computational platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as part of their employment compensation. The stock options have an exercise price of $26.58 per share and a ten-year term, while the RSUs vest over four years. These grants were made under the company's 2021 Inducement Equity Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
none
-
Rhea-AI Summary
Schrödinger (SDGR) will release its Q4 and full-year 2023 financial results on February 28, 2024, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
-
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as a material inducement to their employment. The stock options have an exercise price of $27.41 per share, a ten-year term, and vest over four years, while the RSUs vest over four years as well. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan and were approved by the compensation committee of the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) announces an expanded, three-year software agreement with Eli Lilly and Company. The agreement provides Lilly with large-scale access to Schrödinger’s full suite of technologies to enable and accelerate all stages of drug discovery. Schrödinger also provided an update on its progress across the business and announced its development and operational goals for 2024, including advancing its proprietary pipeline and driving software adoption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none

FAQ

What is the current stock price of Schrodinger (SDGR)?

The current stock price of Schrodinger (SDGR) is $20.84 as of November 22, 2024.

What is the market cap of Schrodinger (SDGR)?

The market cap of Schrodinger (SDGR) is approximately 1.5B.

What does Schrodinger, Inc. do?

Schrodinger, Inc. provides advanced molecular simulations and enterprise software solutions for pharmaceutical, biotechnology, and materials science research.

When was Schrodinger, Inc. founded?

Schrodinger, Inc. was founded in 1990.

What are the main segments of Schrodinger’s business?

Schrodinger operates through two main segments: Software and Drug Discovery.

How does Schrodinger generate revenue?

Schrodinger generates revenue from software sales, research funding, and milestone payments from drug discovery collaborations.

What industries does Schrodinger’s software cater to?

Schrodinger’s software caters to the life sciences industry and materials science industries.

What are some of Schrodinger’s recent achievements?

Schrodinger has made significant advancements in scientific research, enhancing drug discovery processes and establishing impactful partnerships in various fields.

Where are Schrodinger’s operations located?

Schrodinger has operations in the U.S., Europe, Japan, and India.

What is Nimbus Therapeutics?

Nimbus Therapeutics is a biotech company co-founded by Schrodinger, focusing on innovative drug discovery.

How has Schrodinger contributed to scientific research?

Schrodinger's researchers have contributed hundreds of peer-reviewed publications, often significantly cited in their fields.

What makes Schrodinger's software unique?

Schrodinger's software provides predictive power that accelerates research and development, reduces costs, and enables groundbreaking discoveries in drug discovery and materials science.

Schrodinger, Inc.

Nasdaq:SDGR

SDGR Rankings

SDGR Stock Data

1.51B
62.15M
2.39%
96.24%
12.22%
Health Information Services
Pharmaceutical Preparations
Link
United States of America
NEW YORK